Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors

Next Previous
Trial Profile

A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMGN 289 (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoGen

    • Most Recent Events

    • 24 Apr 2015 Status changed from recruiting to discontinued according to an ImmunoGen media release.
    • 25 Apr 2014 Dose escalation is ongoing in this trial, according to an ImmunoGen media release.
    • 31 Jan 2014 Data presentation and/or development decisions for IMGN-289 are anticipated in the second half of 2014, according to an ImmunoGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top